Table 1.
Immune response to influenza vaccines in people with different health conditions
| Reference | Study population | Country | Sample size | Season | GMT (95%CI) | Seroprotection /seroconversion rate (%) (95%CI) | Test strains |
|---|---|---|---|---|---|---|---|
| de Lavallade H. et al.(2010)98 | B-cell malignancies vs. recipients of allogeneic hematopoietic stem cell transplant vs. chronic myeloid leukemia vs. healthy adults | UK | 28 vs.22 vs.20 vs.24 | 2009 | 17.7 (8.7-35.7) vs. 41.8 (14.5-120.3) vs. 100.4 (54.2-186.0) vs. 362.0 (216.4-605.5)* | 39.3 (21.2-57.4) vs. 45.5 (24.6-66.3) vs. 85.0 (69.4-100) vs.100* | A/H1N1+ AS03 adjuvant |
| Meier S. et al. (2011)99 | Immunocompromised children vs. immunocompetent children | Switzerland | 9 vs.51 | 2009-2010 | 237(61-921) vs. 350(251-487)* | 89(52-100) vs. 98(90-100)* | A/H1N1 |
| Candon S. et al.(2009)100 | Recipients of renal transplant vs. healthy adults | France | 66 vs.19 | 2005-2006 | 573 ± 417 vs. 821 ± 341a* | 9.5% vs. 57.9% b * | A/H1N1 |
| 127 ± 230 vs. 139 ± 111 a* | 21.5% vs. 57.9% b * | A/H3N2 | |||||
| 174 ± 159 vs. 184 ± 106 a* | 19.7% vs. 26.3% b * | B | |||||
| Brakemeier S. et al.(2012)101 | Renal allograft recipients vs. healthy adults | Germany | 58 vs.20 | 2009-2010 | 96.5 (72.1–120.9) vs. 406.4 (366.3–445.7)* | 34.5% vs. 91 %* | A/H1N1+ AS03 adjuvant |
| Duchini A. et al.(2001)102 | Liver Transplant Recipients vs. patients With Cirrhosis vs. healthy adults | USA | 20 vs. 14 vs. 9 | 1999-2000 | 52 (24-109) vs. 61 (30-125) vs. 65 (28-149) | 25% vs. 43% vs. 56% | A/H1N1 |
| 56 (27-115) vs. 216 (95-489) vs. 321 (144-710)* | 15% vs. 21% vs. 89%* | A/H3N2 | |||||
| 43 (23-81) vs. 119 (48-292) vs. 92 (37-225) | 30% vs. 69% vs. 56% | B | |||||
| Diepersloot R. J. et al.(1987)103 | Diabetic patients vs. healthy adults | Netherlands | 145 vs.24 | 1987 | - | 64% vs. 66%c | A/H1N1 |
| 110 vs.20 | - | 85% vs. 90%c | A/H3N2 | ||||
| 126 vs.24 | - | 57% vs. 50%c | B | ||||
| el-Madhun A. S. et al.(1998)104 | Juvenile diabetic patients vs. healthy juveniles | Norway | 5 vs.5 | 1998 | 211 vs. 139 | 100% vs. 100% | A/H1N1 |
| 184 vs. 211 | 100% vs. 100% | A/H3N2 | |||||
| 121 vs. 211 | 80% vs. 80% | B | |||||
| Saito T. et al. (2015)105 | Duchenne muscular dystrophy patients vs. healthy healthcare workers | Japan | 44 vs. 41 | 2009 | 75 vs. 69 | 70% vs. 73% | A/H1N1 |
| Agrati C. et al. (2012)106 | HIV patients vs. healthy healthcare workers | Italy | 67 vs. 65 | 2012 | 109.9 vs.106.9 | 100% vs. 98.4% | A/H1N1+ MF59 adjuvant |
Seroprotection rate = percentage of subjects with post-vaccination titer≥40; Seroconversion rate = percentage of subjects with either a pre-vaccination HI titer <1:10 and post-vaccination HI titer≥1:40 or a pre-vaccination HI titer≥1:10 and a minimum 4-fold increase in post-vaccination HI titer; “-”: Data not shown; a Mean antibody titers (x ± SD); b Percentage of subjects with post-vaccination titer≥1:50; c Percentage of subjects with post-vaccination titer>1:100; *P < .05;
Abbreviations: GMT = geometric mean titer; CI = confidence interval; HI = hemagglutination inhibition.